Literature DB >> 3874198

The antimicrobial activity of cefpirome, a new cephalosporin.

R Wise, J M Andrews, C Cross, L J Piddock.   

Abstract

The activity of the extended spectrum cephalosporin cefpirome (HR 810) was compared with that of other beta-lactams and gentamicin. A total of 524 clinical isolates and strains known to be resistant to certain agents were studied. Against the Enterobacteriaceae, Haemophilus influenzae and Neisseria spp. cefpirome was highly active (MIC90 less than or equal to 0.5 mg/l), generally being as active or slightly more active than ceftazidime and cefotaxime, and 8 to 32 times more active than cefuroxime. Against Pseudomonas aeruginosa cefpirome (MIC90 8 mg/l) was four-fold less active than ceftazidime. Staphylococcus aureus was susceptible to cefpirome (MIC90 2 mg/l) and cefpirome was the only cephalosporin tested with significant activity against Lancefield Group D streptococci. Bacteroides spp. (with the exception of Bact. ureolyticus) were resistant to cefpirome. The compound was bactericidal to all the susceptible strains studied with the exception of Lancefield Group D streptococci. The major target site for cefpirome was PBP 3 and the protein binding was low.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3874198     DOI: 10.1093/jac/15.4.449

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery.

Authors:  Doris Hutschala; Keso Skhirtladze; Andreas Zuckermann; Wilfried Wisser; Peter Jaksch; Bernhard Xaver Mayer-Helm; Heinz Burgmann; Ernst Wolner; Markus Müller; Edda M Tschernko
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  Intraperitoneal penetration of cefpirome.

Authors:  J Kavi; J P Ashby; R Wise; I A Donovan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

3.  In vitro activity of cefpirome compared with other third generation cephalosporins against nosocomial isolates in Argentina.

Authors:  J M Casellas; M Goldberg; N Orellana; M I Morosini; M C Negri; S Arduino
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

Review 4.  In vitro antibacterial effects of cephalosporins.

Authors:  J D Williams; F Moosdeen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  Comparative in vitro activity of cefpirome (HR 810) against gram-positive isolates from cancer patients.

Authors:  K V Rolston; G P Bodey
Journal:  Infection       Date:  1986 May-Jun       Impact factor: 3.553

Review 6.  The epidemiology of infections in intensive care units.

Authors:  A M Emmerson
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 7.  Cefpirome clinical pharmacokinetics.

Authors:  L C Strenkoski; D E Nix
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

8.  Bactericidal activity of cefpirome (HR 810) against 513 gram-negative bacteria isolated from blood of septicemic patients.

Authors:  M G Bergeron; M Bernier
Journal:  Infection       Date:  1994 Jul-Aug       Impact factor: 3.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.